GlassScriptPhysician profile
Samar R Sankari
NPI 1013947241
$7,557.53
in general payments reported to CMS, 2019-2025
29 companies · $926 in 2025
The $926 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,631 · 2020: $493 · 2021: $1,036 · 2022: $1,499 · 2023: $987 · 2024: $986 · 2025: $926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,899.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,898.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $1,606.43 | 2019-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $1,182.85 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $985.45 | 2019-2025 | Jardiance, Mounjaro, Lyumjev |
| Sanofi-Aventis U.S. LLC | $697.04 | 2019-2023 | |
| Abbott Laboratories | $650.82 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $557.56 | 2019-2025 | Evenity, Prolia, Prolia |
| Astrazeneca Pharmaceuticals LP | $212.25 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.91 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $196.49 | 2019-2023 | |
| Abbvie INC. | $172.84 | 2021-2025 | Synthroid |
| Janssen Pharmaceuticals, INC | $146.42 | 2019-2022 | |
| Medtronic, INC. | $119.06 | 2023-2025 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $93.54 | 2021-2024 | Gvoke Hypopen, Recorlev |
| Insulet Corporation | $87.72 | 2019-2025 | Omnipod |
| Corcept Therapeutics | $86.82 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $64.60 | 2024-2025 | Unithroid |
| Janssen Scientific Affairs, LLC | $64.50 | 2023 | |
| Tandem Diabetes Care, INC. | $64.43 | 2020-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic Minimed, INC. | $64.30 | 2019 | |
| Merck Sharp & Dohme LLC | $58.28 | 2019 | |
| Cequr Corporation | $57.50 | 2023 | Cequr Simplicity |
| Ibsa Pharma INC. | $43.90 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $30.24 | 2022 | |
| Eusa Pharma (US) LLC | $30.24 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $17.93 | 2021 | |
| Sequel Med Tech, LLC | $16.95 | 2025 | Twiist |
| Bayer Healthcare Pharmaceuticals INC. | $15.98 | 2023 | |
| Antares Pharma, INC. | $15.91 | 2021 | |
| Shire North American Group INC | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samar Sankari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.